The prospect of treating neurological diseases by 'editing' the human brain. (Illustration photo. Source: iStock) |
Over the past two years, several mouse experiments using CRISPR and its variants have shown promise in treating neurological disorders.
Experts expect human clinical trials to begin within the next few years. “The data has never been more promising,” said Monica Coenraads, director of the Rett Syndrome Research Foundation in the US. “This is becoming less and less science fiction and more a reality.”
Unlike the liver or blood, the brain is protected by a blood-brain barrier, making it difficult to introduce gene editing components. However, several research groups have recorded positive results. Last July, an experiment on mice with the disease alternating hemiplegia in children showed that “prime editing” technology could repair about half of the cortex, reducing seizures, improving cognition and movement, and extending lifespan.
Other groups are also testing in mice for Huntington’s disease, Friedreich’s ataxia, and gene mutations that cause epilepsy or mental retardation. In these cases, editing the natural copy of a gene directly is considered safer than adding a new copy, which can be toxic.
Scientists hope to test the therapy on patients with Rett syndrome or AHC within five years. The method will likely rely on the AAV9 virus to deliver the gene-editing component into the brain, but immunological risks remain a major challenge. In addition, the US biotechnology industry is experiencing a financial crisis, which has gradually reduced funding for research on this expensive therapy.
“Funding is running out,” says Ms. Coenraads. “But we have to persevere and continue to produce good data.”
Source: https://baoquocte.vn/vien-canh-dieu-tri-benh-than-kinh-bang-cach-chinh-sua-nao-nguoi-324673.html
Comment (0)